Lord, Abbett & Co. LLC Tg Therapeutics, Inc. Transaction History

Lord, Abbett & Co. LLC

$31.1 Billion
Q2 2025

A detailed history of Lord, Abbett & Co. LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 557,966 shares of TGTX stock, worth $15.1 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

557,966

Holding current value

$15.1 Million

% of portfolio

0.06%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$33.37 - $45.51 $18.6 Million - $25.4 Million	557,966 New	557,966 $20.1 Million
Q1 2022 May 13, 2022	SELL	$7.81 - $20.45 $1.52 Million - $3.99 Million	-195,212 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$15.2 - $35.51 $17 Million - $39.7 Million	-1,118,576 Reduced 85.14%	195,212 $3.71 Million
Q3 2021 Nov 09, 2021	SELL	$21.78 - $40.45 $33 Million - $61.2 Million	-1,512,974 Reduced 53.52%	1,313,788 $43.7 Million
Q2 2021 Aug 11, 2021	SELL	$32.5 - $48.96 $60.7 Million - $91.5 Million	-1,868,539 Reduced 39.8%	2,826,762 $110 Million
Q1 2021 May 11, 2021	BUY	$41.61 - $54.3 $10.6 Million - $13.8 Million	254,842 Added 5.74%	4,695,301 $226 Million
Q4 2020 Feb 09, 2021	SELL	$25.27 - $54.9 $14.1 Million - $30.6 Million	-558,067 Reduced 11.16%	4,440,459 $231 Million
Q3 2020 Nov 12, 2020	BUY	$18.49 - $27.24 $67.9 Million - $100 Million	3,671,841 Added 276.77%	4,998,526 $134 Million
Q2 2020 Aug 14, 2020	BUY	$8.9 - $21.84 $3.39 Million - $8.32 Million	380,921 Added 40.28%	1,326,685 $25.8 Million
Q1 2020 May 14, 2020	BUY	$7.14 - $15.99 $6.75 Million - $15.1 Million	945,764 New	945,764 $9.31 Million

Others Institutions Holding TGTX

# of Institutions

404

Shares Held

92M

Call Options Held

2.24M

Put Options Held

1.77M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $3.94B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Account

Lord, Abbett & Co. LLC Tg Therapeutics, Inc. Transaction History